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Abstract
Cancer cell lines have been shown to be reliable tools in genetic studies of breast cancer, and the characterization of these
lines indicates that they are good models for studying the biological mechanisms underlying this disease. Here, we describe
the molecular cytogenetic/genetic characterization of two sister rat mammary tumor cell lines, HH-16 cl.2/1 and HH-16.cl.4,
for the first time. Molecular cytogenetic analysis using rat and mouse chromosome paint probes and BAC/PAC clones
allowed the characterization of clonal chromosome rearrangements; moreover, this strategy assisted in revealing detected
breakpoint regions and complex chromosome rearrangements. This comprehensive cytogenetic analysis revealed an
increase in the number of copies of the Mycn and Erbb2 genes in the investigated cell lines. To analyze its possible
correlation with expression changes, relative RNA expression was assessed by real-time reverse transcription quantitative
PCR and RNA FISH. Erbb2 was found to be overexpressed in HH-16.cl.4, but not in the sister cell line HH-16 cl.2/1, even
though these lines share the same initial genetic environment. Moreover, the relative expression of Erbb2 decreased after
global genome demethylation in the HH-16.cl.4 cell line. As these cell lines are commercially available and have been used
in previous studies, the present detailed characterization improves their value as an in vitro cell model. We believe that the
development of appropriate in vitro cell models for breast cancer is of crucial importance for revealing the genetic and
cellular pathways underlying this neoplasy and for employing them as experimental tools to assist in the generation of new
biotherapies.
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Introduction
Breast cancer is one the most commonly occurring cancers
among women and has been described as a molecularly
heterogeneous disease. Genetic studies of breast cancer rely on
the use of primary tumors, paraffin-embedded samples or cell
lines. Breast cancer cell lines present the great advantage of being
readily available, and the full characterization of cell line models
has been shown to provide valuable insights regarding the degree
of complexity of the polygenetic etiology of breast cancer and the
biological mechanisms that characterize this disease [1]. Chem-
ically induced carcinogenesis of the rat mammary gland has been
used extensively to investigate breast cancer. In rat models,
the carcinogenic compound 7,12-dimethylbenz[a]anthrazene
(DMBA) is frequently used to induce tumors, and DMBA-
induced rat mammary tumors and sarcomas are useful cancer
models [2,3,4]. Using the evolutionary conservation of gene
segments as a guide, animal models, such as the rat, constitute
powerful tools to decipher pathways and genes involved in
tumorigenesis [4]. Moreover, researchers now have access to
powerful web servers and databases in which syntenic regions can
be easily identified and associated with a great amount of
information regarding human and rat genetics. The available
animal tumor cell lines are often poorly characterized from a
cytogenetic/genetic point of view, reducing their usefulness as cell
models.
Here, we present the molecular cytogenetic/gene expression
characterization of two DMBA-induced rat mammary tumor cell
lines: the HH-16 cl.2/1 fibrosarcoma cell line and the HH-16.cl.4
adenocarcinoma cell line. The choice of these cell lines was based
on two factors: first, the reliability of both cell lines as models has
been demonstrated in investigations of the effects of glucocorticoid
hormones on cell morphology and proliferation and the stability of
cultured rat cells after infection with Moloney murine sarcoma
virus [5,6,7]; second, these cell lines are commercially available to
the entire scientific community, and when they are properly
characterized, they may constitute reliable cell models for breast
cancer research.
Performing a chromosome count constitutes a mandatory step
in the cytogenetic characterization of cell lines, allowing an
overview of their genetic variability and stability. Of the two
investigated cell lines, only HH-16 cl.2/1 presents low polyploidy
levels, indicating a certain degree of stability, and for this reason,
detailed cytogenetic characterization was restricted to this cell line.
The methodology used in this study included fluorescent in situ
hybridization with rat and mouse chromosome paint probes to
identify chromosomal rearrangements, complemented with BAC/
PAC clones that assisted in the accurate detection of the
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chromosome abnormalities. The increase in the number of copies
(determined with specific BAC clones) of the Mycn and Erbb2 genes
detected in this analysis was of particular note. The development
and progression of cancer are characterized by a variety of genetic
modifications in mechanisms that control genome stability,
including alterations in oncogenes [8]. ERBB2 oncogene ampli-
fication constitutes one of the most important genetic alterations
associated with human breast cancer and was found to be
correlated with poor patient prognosis by Slamon and colleagues
[9]. MYCN oncogene amplification is characteristic of human
neuroblastomas, being found in 20% of these childhood cancers,
and has been observed to be involved in breast tumorigenesis, with
up-regulation being detected in inflammatory breast cancer [10].
In the present study, the amplification status of the rat counterpart
Erbb2 and Mycn genes was analyzed in the HH-16 cl.2/1 and HH-
16.cl.4 rat cell lines by fluorescent in situ hybridization, and the
expression of these genes was assessed by real-time reverse
transcription quantitative PCR (RT-qPCR) complemented and
validated with an RNA fluorescent in situ hybridization (RNA
FISH) analysis.
Abnormal patterns of DNA methylation have been found in
several types of human cancer. DNA hypermethylation may result
in gene expression silencing and loss of protein function as well as
being associated with cancer progression [11]. Currently,
epigenetic therapies aim to restore hypomethylation and to reverse
gene silencing induced by hypermethylation [12]. A cytosine
analogue established as a potent inhibitor of DNA methylation, 5-
Aza-29-Deoxicitidine (decitabine), [13] has been used in both
preclinical models and in cancer patients [14]. However, global
demethylation effects in tumor cells treated with this agent remain
poorly understood. Early studies suggest that the loss of DNA
methylation is a common event in tumorigenesis [15,16]. To
evaluate global genome demethylation effects on gene expression
in the studied rat tumor cell lines, cells were treated with 5-Aza-29-
Deoxicitidine, and Mycn and Erbb2 expression was subsequently
determined.
The cytogenetic and genetic characterization of the HH-16 cl.
2/1 and HH-16.cl.4 rat mammary cell lines, complemented with
expression profiling analysis of the Mycn and Erbb2 oncogenes and
verification of the influence of global demethylation on the
expression of these genes validates the use of these cell lines as
models for breast cancer research.
Materials and Methods
Cell culture and chromosome preparation
The HH-16 cl.2/1 and HH-16.cl.4 cell lines were obtained
from the German Collection of Microorganisms and Cell Cultures
(DSMZ). Both cell lines were established from ascitic fluid of the
same female Sprague-Dawley rat with a mammary tumor
produced by injection of cultured cells from a DMBA-induced
mammary tumor. When injected into rats, HH-16.cl.2/1 cells
have been found to produce fibrocarcinomas while HH-16.cl.4
cells generate adenocarcinomas. Both cell lines were grown in
RPMI 1640 supplemented with 10% FCS, 1% 200 mM L-
Glutamine and 1% of a Penincilin-Streptomycin antibiotic
mixture (all from Gibco, Life Technologies). The HH-16.cl.4 cell
medium was also supplemented with 1% 100 mM Sodium
Pyruvate MEM (Gibco, Life Technologies). Both cultures were
passaged at confluence using 0.25% trypsin (16) with EDTA in
Hanks’ balanced salt solution (Gibco, Life Technologies). For both
cell lines, metaphase chromosomes were obtained by treatment
with colcemide (10 mg/ml, Invitrogen, Life Technologies) for
45 minutes followed by hypotonic solution (0,05 M KCl, 30 min-
utes, 37uC) and fixation with methanol:acetic acid (3:1), and the
samples were then dropped onto microscope slides.
GTD-banding
Air-dried slides from the HH-16 cl.2/1 cell line were aged at
65uC overnight and then subjected to standard G-banding
procedures with trypsin [17]. DAPI was used for staining (instead
of routine Giemsa staining) to obtain a better contrast [18].
Inversion of the DAPI color in Adobe Photoshop (version 7.0)
revealed the chromosome G-banding pattern (GTD-banding, G-
bands revealed by trypsin with DAPI).
Chromosome painting
Chromosome paint probes from Rattus norvegicus (RNO) and Mus
musculus (MMU) were kindly provided by Dr. Johannes Wienberg
and Dra. Andrea Kofler from Chrombios GmbH, Germany.
Chromosome-specific probes were labeled by DOP-PCR using the
universal primers 6MW (for RNO paints) and F/S (for MMU
paints) together with incorporation of digoxigenin-11-dUTP
(Roche) or biotin-16-dUTP (Roche).
Fluorescent in situ hybridization experiments were performed
according to [19]. RNO paint probes were hybridized to
chromosomes from both the HH-16 cl.2/1 and HH-16.cl.4 cell
lines while MMU paint probes were only hybridized to HH-16
cl.2/1 chromosomes. The most stringent post-hybridization wash
was 50% formamide/26SSC at 37uC, and probe detection was
performed using antidigoxigenin-59TAMRA (Roche) and FITC
conjugated with avidin (Vector Laboratories).
Probe construction from BAC/PAC clones and FISH
BAC and PAC clones were obtained from the BACPAC
Resources Center from Children’s Hospital Oakland Research
Institute (http://bacpac.chori.org/). The acquired clones were
RP31-262B4, CH230-208E5, RP31-202O5, RP31-039D3,
CH230-10B5 (for rat chromosome 6); CH230-174M18, CH230-
9A5, CH230-215E5, CH230-27O13, CH230-165C24, CH230-
117H20 (for rat chromosome 15); and CH230-162I16, CH230-
276G18 and CH230-305O21 (rat Erbb2 predicted clones). DNA
from the clones was purified using QUIAGEN Plasmid Purifica-
tion Kit as recommended by the manufacture (QIAGEN) and
labeled with tetramethyl-rhodamine-5-dUTP (Roche) by Nick
Translation (Abbott) for 2 hours at 15uC. Labeled probes were
precipitated with an excess of sonicated normal rat genomic DNA
and dissolved in hybridization solution. FISH procedures were
performed as described in the Chromosome Painting section using
chromosome preparations of the HH-16 cl.2/1 and HH-16.cl.4
cell lines.
For rat Erbb2, three BAC clones were selected in silico using the
NCBI Map Viewer online resource (http://www.ncbi.nlm.nih.
gov/mapview/) and then tested for the presence of Erbb2 and
mapped by FISH (see Figure S1). Briefly, a rat Erbb2 genomic
sequence obtained from the Ensembl database (http://www.
ensembl.org/) was used to design specific primers for the
amplification of this gene in the three BAC clones. PCR was
performed with purified plasmid DNA from rat BAC clones (as
described above), and PCR products with the predicted sizes were
excised from 1.2% agarose gels, purified and sequenced. FISH
procedures were performed as described above.
FISH image capture, processing and analysis
Chromosomes were observed using a Zeiss AxioImager Z1
microscope, and images were captured using an Axiocam MRm
Erbb2 In Vitro Cell Model
PLoS ONE | www.plosone.org 2 January 2012 | Volume 7 | Issue 1 | e29923digital camera with LSM 510 software (version 4.0 SP2). Digitized
photos were prepared in Adobe Photoshop (version 7.0); image
optimization included contrast and color adjustments that affected
the whole image equally. Karyotypes were constructed following
the nomenclature for rat chromosomes described by Levan [20],
and chromosome rearrangements were described according to
ISCN (2009) [21].
Gene amplification criteria
Gene amplification was calculated based on the ratio between
the number of gene signals and the number of chromosomes
harboring that gene. Mycn amplification was defined for Mycn/
RNO6$2 and Erbb2 amplification by Erbb2/RNO10$2, with 2
being the cut-off value for both. Rat PAC clone RP31-202O5 was
used to identify the Mycn gene, rat BAC clone CH230-162I16
allowed detection of Erbb2, and rat paint probes were used to
identify chromosomes 6 and 10. Additional copies of each gene,
detected by FISH at levels equal to or no more than 4-fold higher
(when compared with normal gene number) were considered to be
a Mycn or Erbb2 gain.
RNA isolation and reverse transcription quantitative real-
time PCR
Total RNA from rat cell lines was isolated using the mirVana
Isolation Kit (Ambion) following the manufacturer’s recommen-
dations. Expression experiments were performed using the
TaqManH RNA-to-CT
TM 1-Step Kit (Applied Biosystems). The
TaqMan Gene Expression Assay Mixes (primer/probe sets) used
were beta-actin (Rn00667869_m1) and glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH, Rn01749022_g1) as reference
genes and Mycn (Rn01473353) and Erbb2 (Rn00566561_m1) as
targets (all assays were from Applied Biosystems). The 20 ml
reactions included 2 ml of RNA sample (50 ng/ml), 1 ml of the
primer/probe assay mixture, 10 ml of PCR Master Mix, 0.5 mlo f
RT enzyme mix (Applied Biosystems) and 6.5 ml of DEPC-treated
water. The reactions were carried out in a 96-well optical plate at
48uC for 15 min and 95uC for 10 min, followed by 40 cycles of
95uC for 15 s and 60uC for 1 min. PCR was carried out in the
ABI 7500 Fast Real Time PCR system (Applied Biosystems). All
reactions were performed in triplicate, and negative controls
(without template) were run for each master mix. SDS software
version 1.4 (Applied Biosystems) was applied for comparative
analysis, and the relative expression level was normalized with
multiple reference genes. The 2
2DDCT method [22] was used to
calculate fold changes in the expression levels of the genes of
interest using a control RNO sample as a calibrator. Expression
fold changes$3 were considered relevant.
Statistical analysis
Student’s t-test was used to compare the data obtained. Values
were expressed as the mean 6 SD, and differences were
considered statistically significant at p,0.05, representing the
95% confidence interval of the mean expression level.
RNA fluorescent in situ hybridization
RNA FISH was performed using the QuantiGene ViewRNA
plate-based assay kit (Panomics) following the manufacturer’s
recommendations with some modifications. Briefly, HH-16 cl.2/
1 and HH-16.cl.4 cells were grown on polysine coated glass slides,
fixed using 8% formaldehyde, dehydrated in ethanol (50%–70%–
100%) and held at 4uC overnight. Then, cells were rehydrated,
permeabilized and hybridized as recommended, except that
protease digestion was optimized for each cell line. The RNA
target was human ERBB2 (Panomics), and the reference RNA
was human/rat/mouse 18S RNA (Panomics). Confocal fluores-
cence images were captured on an LSM 510 META with a Zeiss
Axio Imager Z1 microscope and LSM 510 software (version 4.0
SP2). For each scan, the same microscope settings were employed
for all images to normalize the results. The lasers used were as
follows: argon (488 nm) set at 12.9%, helium–neon (543 nm) set
at 50.8% and Diode (405 nm) set at 9.9%. The pinhole was set to
96 mm (1.02 airy units) for argon laser, 102 mm (0.98 airy units)
for helium–neon laser and 112 mm for the Diode laser using a
636 objective. Images were captured at a scan speed of 5
(3.30 ms) with 1 mm thick Z sections and processed using the ‘‘3D
Viewer’’ plug-in for ImageJ. Twenty slide fields were randomly
selected and analyzed by counting the number of signals in each
cell.
5-Aza-29-Deoxicitidine demethylation
For global genome demethylation, the media for the HH-16
cl.2/1 and HH-16.cl.4 rat cell lines were supplemented with
different concentrations of 5-Aza-29-Deoxicitidine (Sigma) (3 mM,
10 mM and 30 mM) for 72 hours. Every 24 hours, the medium was
changed, followed by the addition of 5-Aza-29-Deoxicitidine. After
the 72 h period, a sample of the cells was collected for RNA
extraction, and remaining cells were allowed to grow without drug
treatment for another 72 hours, after which they were also
subjected to RNA extraction. Additionally, the HH-16 cl.2/1 and
HH-16.cl.4 cell lines were grown without 5-Aza-29-Deoxicitidine
as controls.
Results
HH-16 cl.2/1 and HH-16.cl.4 morphological features and
ploidy
Phase contrast microscopy analysis of the HH-16 cl.2/1 cell line
revealed a fibroblastoid cell morphology, with the cells growing in
a criss-cross pattern (Figure 1A). The HH-16.cl.4 line presented
distinct cell morphology, with epitheloid-shaped cells growing in
monolayer (Figure 1B).
Chromosome number analysis of the HH-16 cl.2/1 rat
mammary fibrosarcoma cell line was carried out throughout the
examination of 75 cells. The results show that this cell line presents
a near diploid karyotype (Figure 1C), with 2n=42 being the
normal chromosome number for this species. The HH-16 cl.2/1
modal chromosome number is 40–41 (2n=39–43 is the ploidy
referenced in the available cell line description in the DSMZ
database), and the polyploidy levels of this line are reduced (less
than 3%), with only two cells being observed with a nearly
tetraploid karyotype, containing 79 and 82 chromosomes.
Chromosome number analysis was also performed for the HH-
16.cl.4 rat mammary tumor cell line based on examination of 75
cells. This cell line presents a nearly tetraploid karyotype
(Figure 1D) with a modal number of 79–80 (4n=79–84 is the
ploidy referenced in the available cell line description in the
DSMZ database). When compared with the sister cell line, HH-
16.cl.4 shows a wider range of cells with different chromosome
numbers, with approximately 9% of cells being observed to have a
nearly triploid karyotype (60–68 chromosomes) and 2% of cells
exhibiting a nearly heptaploid karyotype (151–155 chromosomes).
This variability in ploidy might be reflected in significant levels of
karyotypic heterogeneity within this cell line, which are indicative
of a higher order of complexity and instability when compared
with the HH-16 cl.2/1 cell line. This observation restricted large-
scale cytogenetic characterization to only the HH-16 cl.2/1 cell
line, which apparently presents a more ‘‘stable’’ karyotype.
Erbb2 In Vitro Cell Model
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Identification of clonal chromosome rearrangements. A
combination of G-banding and fluorescent in situ hybridization
was used in the cytogenetic characterization of clonal
rearrangements for HH-16 cl.2/1. Paint probes for each rat
chromosome (RNO1-20, X) and from mice (MMU19) were
successfully hybridized to HH-16 cl.2/1 cell line chromosomes
(Figure 2A–E), revealing a total of 13 rearrangements, both
numeric and structural in character, involving chromosomes
RNO1, RNO3, RNO4, RNO6, RNO7, RNO11, RNO13,
RNO15, RNO18, RNO19 and RNOX. Three numerical
changes were observed, involving a whole chromosome gain (+1)
and two losses (2X, 218), with X chromosome monosomy being
one of the most representative rearrangements. The rat
chromosomes associated with greater numbers of
rearrangements were RNO1, RNO6, RNO15 and RNO19.
More structural than numerical aberrations were observed, and
derivative chromosomes resulting from translocations were the
predominant structural abnormalities. The most frequent
structural chromosome rearrangements identified using this
approach were as follows: t(3;11)(p12;p12), der(4;15)(q10;p10),
der(7)t(1;7)(q51;q36), del(13)(p13) and der(19)t(6;19). Almost all
rearrangements were unbalanced, involving gains and losses of
chromosome segments. G-banding analysis allowed us to
determine that the region of chromosome 1 involved in the
rearrangement der(7)t(1;7)(q51;q36) was the terminal region. To
confirm this analysis, the MMU19 paint probe was used because it
is syntenic to this region in the rat. This approach confirmed that
the region presented by the derivative chromosome is 1qterR1q51
(Figure 2E).
High-resolution chromosome rearrangement
characterization and identification of breakpoint
regions. To refine the cytogenetic characterization, a total of
8 BAC and 3 PAC clones were hybridized to HH-16 cl.2/1 cell
line chromosomes. The selected clones contained regions of rat
chromosomes 6 (RP31-262B4, CH230-208E5, RP31- 202O5,
RP31-039D3, CH230-10B5) and 15 (CH230-174M18, CH230-
9A5, CH230-215E5, CH230-27O13, CH230-165C24, CH230-
117H20), which were physically mapped in a previous study [23].
The BAC/PAC results allowed the identification of the breakpoint
regions of the derivative chromosomes involving RNO6 to
der(19)t(6;19)(q14;q12), der(19)t(4;19)(q31;p11)t(6;19)(q14;q12) and
der(18;19)t(18;19)(p10,q10)t(6;19)(q14;q12), assigning the location
of the breakpoint in all of these chromosomes to band 6q14, above
the region included within clone RP31-262B4 (Figure 3).
Concerning the analysis of RNO15, BAC mapping allowed the
identification of these breakpoint chromosome regions involved
in the der(4;15)(q10;p10) and der(15)del(15)(p11)t(1;15)(q12;q24)
(Figure 4). Regarding the first derivative chromosome, it was
possible to verify that it involved the entire chromosome 15p arm in
a whole-arm translocation with chromosome 4 (Figure 4A). Con-
cerning der(15)del(15)(p11)t(1;15)(q12;q24), BAC clones assisted
in the identification of chromosome regions 15p11 and
15q24, which were involved in the formation of the derivative
chromosome (Figure 4B–D). Moreover, the BAC analysis allowed
the detection of a complex rearrangement in chromosome 15
Figure 1. Morphology (610) and ploidy of HH-16 cl.2/1 and HH-16.cl.4 cells. HH-16 cl.2/1 cell line presenting a fibroblastoid cell
morphology with the cells growing in a criss-cross pattern (A), and HH-16.cl.4 cells morphology showing epitheloid shaped cells (B). Chromosome
count analysis revealed a near-diploid karyotype with low level of polyploidy in HH-16 cl.2/1 (C) while a wide range of different chromosome numbers
were observed in HH-16.cl.4, being the most representative the near-tetraploid karyotype (D).
doi:10.1371/journal.pone.0029923.g001
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physical mapping of all of the BAC clones, two of them (CH230-
117H20 and CH230-9A5) were found to have assumed different
cytogenetic positions than expected (Figure 4E). The type of
structural rearrangement that would most likely explain these
results is a pericentric inversion. However, the remaining BAC
clones used in this chromosome analysis were shown to assume
the expected locations, meaning that the region between CH230-
117H20 and CH230-9A5 maintained its expected order,
suggesting a more complex rearrangement. We suggest the
occurrence of a second pericentric inversion event involving two
other breakpoints. Nevertheless, we cannot discard other possible
events leading to the observed derivative chromosome. An
interesting characteristic was that both RNO15 homologs,
der(4;15)(q10;p10) and der(15)del(15)(p11)t(1;15)(q12;q24), present
this configuration.
Integration of all of the FISH data allowed the construction of
an HH-16 cl.2/1 composite karyotype based on the analysis of 64
cells:
30,42,X,-X, +1 t(3;11)(p12;p12),der(4;15)(q10;p10),der(7)t(1;7)
(q51;q36),del(13)(p13), der(15)del(15)(p11)t(1;15)(q12;q24,der(15)-
inv(15)(p14,p16q23,q25)inv(15)(p12,p14q22,q23)62, 218,
der(18)t(1;18)(q11;q12.3), der(18;19)t(18;19)(p10,q10)t(6;19)(q14;q12),
der(19)t(6;19)(q14;q12), der(19)t(4;19)(q31;p11)t(6;19)(q14;q12)[cp64]
Reconstruction of HH-16 cl.2/1 cell line clonal evolution
The chromosomal structural abnormalities t(3;11)(p12;p12),
del(13)(p13), and der(15)inv(15)(p14,p16q23,q25)(p12,p14q22,
q23)62 as well as the numeric change –X were observed in all
of the cells analyzed (64 cells), suggesting a monoclonal origin of
the tumor cell line. The other most frequent chromosomal
abnormalities were der(19)t(6;19)(q14;q12), found in 45 cells;
Figure 2. Molecular cytogenetic characterization of HH-16 cl.2/1 clonal chromosome rearrangements. Representative images of in situ
hybridization with RNO and MMU paint probes onto HH-16 cl.2/1 metaphases (A–D), highlighting the derivative chromosomes. Derivative
chromosomes are shown in detail (FISH and GTD) (E).
doi:10.1371/journal.pone.0029923.g002
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observed in 20 of the 64 cells analyzed. This analysis permitted
the identification of different cell subclones (Table 1), and
comparison of these subclones allowed inferring ancestral
rearrangements as well as a tentative reconstruction of the
clonal evolution that occurred during tumor progression. The
rearrangements present in all cells were considered to be part of
the ancestral clone (as shown in Figure 5), from which several
branches diverged during tumor progression (karyotype formulas
presented in Table 1).
In silico analysis of breast cancer-related genes present in
breakpoint regions
All of the identified breakpoint regions resulting from clonal
chromosome rearrangements in the HH-16 cl.2/1 cell line are
summarized in Figure S2. An in silico analysis using data from the
Rat Genome Database (http://rgd.mcw.edu; assembly RGSC 3.4)
and Ensembl (http://www.ensembl.org/; assembly RGSC 3.4)
permitted screening of the breakpoint regions of the ancestral
structural rearrangements for the presence of breast cancer-related
genes (summarized in Table S1). With the exception of breakpoint
bands 11p12, 15q22, 15q23, 15q24 and 15q25, all of the other
breakpoints contain genes in the rat genome with human
homologs that have been associated with breast cancer in humans.
Mycn and Erbb2 analysis
Gene amplification. Unlike most gene amplification studies
using FISH, the present analysis was performed in metaphase
chromosomes instead of interphase nuclei. This approach was
advantageous, as it allowed a clear view of aneuploidies and
chromosome rearrangements involving regions harboring the
studied genes to be obtained. RNO6 painting and the rat PAC
clone RP31- 202O5 were used to access the amplification status of
Mycn. RP31-202O5 was earlier confirmed to contain Mycn gene
and mapped to RNO 6q15.3-16 [23] and was also used in this
work for the accurate identification of HH-16 cl.2/1 breakpoint
regions. During HH-16 cl.2/1 cytogenetic characterization, it was
possible to verify that this gene was present in three copies
Figure 3. Molecular characterization of the rearrangements involving RNO6 using BAC/PAC clones. Representative images of in situ
hybridization with BAC/PAC clones onto HH-16 cl.2/1 metaphases (A–C). Chromosome map of the region from bands 6q14 to 6q16, showing the
relative positions of the clones used in this study (not to scale) (D). GTD and RP31-262B4 hybridization on the two normal RNO6 and one derivative
chromosome of a rearranged cell (E).
doi:10.1371/journal.pone.0029923.g003
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derivative chromosomes der(19)t(6;19)(q14;q12), der(18;19)t(18;
19)(p10,q10)t(6;19)(q14;q12),der(19)t(6;19)(q14;q12) and der(19)t(4;
19)(q31;p11)t(6;19)(q14;q12), indicating that a partial trisomy of
RNO6 was involved in a translocation. The derivative
chromosomes were not considered in the estimation of RNO6 for
the Mycn/RNO6 calculation. As can be seen in Table 2, the most
representative ratio was 1.5 (84.6%), corresponding to three Mycn
signals distributed among two normal RNO6 chromosomes and
one derivative chromosome (Figures 6A and 6B). Mycn was not
considered to be amplified in this cell line, while a Mycn gain was
considered to have occurred. The derivative chromosome
der(19)t(6;19)(q14;q12) presenting Mycn was found in the majority
of cells analyzed and, thus, was considered to represent an ancestral
rearrangement (Figure 5). This finding raised the question of its
importance in tumor initiation and progression, as this extra copy of
Figure 4. Molecular characterization of the rearrangements involving RNO15 using BAC clones. Representative images of in situ
hybridization with the BAC clones onto HH-16 cl.2/1 metaphases (A–D). Chromosome map of RNO15 showing the relative positions of the clones
used in this study, and the respective clone positions in the rearranged chromosome (not to scale) (E). GTD and CH230-9A5 and CH230-117H20
hybridization on the derivative chromosomes of a rearranged cell (F).
doi:10.1371/journal.pone.0029923.g004
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cell line, all of the cells analyzed were characterized by a ratio of 1,
presenting four Mycn signals distributed among four RNO6
chromosomes (data not shown). Mycn was also not amplified in
the HH-16.cl.4 cell line.
To investigate Erbb2 gene amplification, the RNO10 paint
probe and CH230-162I16 rat BAC clone were used for FISH
experiments with HH-16 cl.2/1 and HH-16.cl.4 chromosomes.
This BAC clone was selected from a total of three clones acquired
that were validated by PCR isolation followed by sequencing, with
this clone being the only found to contain the Erbb2 gene (Figure
S1). CH230-162I16 was mapped by FISH for the first time in this
study, and it was assigned to RNO 10q32.1, which is the
cytogenetic position of rat Erbb2 determined by Koelsch in 1998
[24]. According to the criteria used, no Erbb2 amplification was
detected in the HH-16 cl.2/1 cell line. The analysis revealed an
Erbb2/RNO10 ratio of 1 in all analyzed cells (Table 2),
corresponding to the presence of two Erbb2 signals distributed
among two RNO10 chromosomes (data not shown). Among the
HH-16.cl.4 cells analyzed (Table 2), the most representative
Erbb2/RNO10 ratio was 1.7 (88.6% of cells), which is near the cut-
off value. In these cells, five Erbb2 signals can be seen to be
distributed among one intact RNO10 (one Erbb2 signal) and two
derivative RNO10 chromosomes with a duplication involving
Erbb2 loci (two Erbb2 signals) (Figures 6C and 6D). As five Erbb2
signals were observed, an Erbb2 gain was considered to have
occurred. An RNO10 polysomy was verified.
RNA expression analysis. The levels of expression of the
Mycn and Erbb2 genes in HH-16 cl.2/1 and HH-16.cl.4 were
determined by one-step real-time RT quantitative PCR (RT-
qPCR), complemented and validated by RNA FISH (for Erbb2).
Figure 7 shows the relative RT-qPCR quantification in terms of
the fold change in Erbb2 and Mycn RNA expression for both cell
lines, which was normalized using multiple reference genes and is
given relative to a calibrator (control RNO sample). All of the
expression values presented in the graph were considered
statistically significant following analysis using Student’s t-test
with a p value,0.05. Regarding Mycn, despite the statistical
significance of the results, the fold changes in gene expression were
low. For the HH-16.cl.4 cell line, a gain of 1.6 was verified, while
for HH-16 cl.2/1, the expression value was below control sample
expression (0.7 SD60.06), corresponding to 1.4 times less
expression than the control sample (Table 2). Only the results
for Erbb2 showed significant expression level changes, especially in
HH-16.cl.4. The increase in Erbb2 expression in HH-16 cl.2/1
was 2.6 fold (close to the cut-off value), and in HH-16.cl.4, Erbb2
was expressed at a level 10.7 times higher than in the control
sample (Table 2). HH-16 cl.2/1 Erbb2 expression was
approximately 4 times lower than in the sister cell line HH-
16.cl.4, with significant expression only being found in the HH-
16.cl.4 rat mammary cell line.
Evaluation of Erbb2 expression was also performed using RNA
fluorescent in situ hybridization in HH-16 cl.2/1 and HH-16.cl.4,
validating the RT-qPCR analysis. This procedure allowed the
visualization of Erbb2 mRNA in individual cells of both cell lines
(Figures 8A and 8B). The number of signals per cell was counted in
20 slide fields for each rat cell line, resulting in a total of 483 cells
being analyzed for HH-16 cl.2/1 and 321 cells being analyzed for
HH-16.cl.4. The results are displayed as the percentages of cells
with total Erbb2 signals falling between four numerical intervals:
[1–5], [6–10], [11–30] and [+30]. Figure 8C shows that 84.5% of
the HH-16 cl.2/1 cells present 1–5 Erbb2 signals, and 60.4% of
HH-16.cl.4 cells present 11–30 Erbb2 signals, with these intervals
being the most representative for each cell line. The mean number
of signals per cell was 3.3 for HH-16 cl.2/1 and 15.2 for HH-
16.cl.4 (Figure 8D and Table 2). These results show that there was
higher expression of Erbb2 in HH-16.cl.4 than in HH-16.cl.2/1,
with 4.6 times higher expression being observed in the former cell
line than in that latter, with is in accordance with the RT-qPCR
data. The advantage of this methodology is the use of single cell
analysis, which showed a wide range of expression in the cells of
both cell lines. In addition to the expression analysis, RNA FISH
permitted us to examine the sub-cellular localization of Erbb2
mRNA. In both rat cell lines, Erbb2 displayed cytoplasmic
localization.
Influence of 5-Aza-29-Deoxicitidine global demethylation
on Mycn and Erbb2 RNA expression
Both cell lines were treated with 5-Aza-29-Deoxicitidine for a
period of 72 h, after which RNA was extracted and used to
evaluate Erbb2 and Mycn expression levels by means of RT-qPCR.
These experiments were normalized with multiple reference genes
Table 1. Karyotypic formulas of the subclones (A to H) presently found in HH-16 cl.2/1 cell line.
Subclone Karyotypic formulas
A 38,42,X,-X,t(3;11)(p12;p12),der(7)t(1;7)(q51;q36),del(13)(p13),der(15)inv(15)(p14,p16q23,q25)inv(15)(p12,p14q22,q23)62,
der(19)t(4;19)(q31;p11)t(6;19)(q14;q12) [6]
B 35,42,X,-X,t(3;11)(p12;p12),der(7)t(1;7)(q51;q36),del(13)(p13),der(15)inv(15)(p14,p16q23,q25)inv(15)(p12,p14q22,q23)62, der(19)t(6;19)(q14;q12)
[14]
C 30,41, X,-X,t(3;11)(p12;p12),der(4;15)(q10;p10),del(13)(p13),der(15)del(15)(p11)t(1;15)(q12;q24),
der(15)inv(15)(p14,p16q23,q25)inv(15)(p12,p14q22,q23)62,der(19)t(6;19)(q14;q12) [9]
D 30,41,X,-X,t(3;11)(p12;p12),der(4;15)(q10;p10),del(13)(p13),der(15)inv(15)(p14,p16q23,q25)inv(15)(p12,p14q22,q23)62, der(19)t(6;19)(q14;q12) [14]
E 30,42,X,-X,t(3;11)(p12;p12),del(13)(p13),der(15)inv(15)(p14,p16q23,q25)inv(15)(p12,p14q22,q23)62, der(19)t(6;19)(q14;q12) [11]
F 39,41,X,-X,t(3;11)(p12;p12),del(13)(p13), der(15)inv(15)(p14,p16q23,q25)inv(15)(p12,p14q22,q23)62,
der(18)t(1;18)(q11;q12.3),der(19)t(6;19)(q14;q12) [3]
G 38,42,X,-X,t(3;11)(p12;p12),del(13)(p13),der(15)inv(15)(p14,p16q23,q25)inv(15)(p12,p14q22,q23)62, der(18;19)t(18;19)(p10,q10)t(6;19)(q14;q12),218
[4]
H 42,X,-X,t(3;11)(p12;p12),del(13)(p13),der(15)inv(15)(p14,p16q23,q25)inv(15)(p12,p14q22,q23)62, der(19)t(6;19)(q14;q12),+1 [3]
The karyotype formulas correspond to the different subclones identified in HH-16 cl.2/1 cell line allowing the identification of ancestral chromosome rearrangements
and to deduce the hypothetic clonal evolution shown in Figure 5.
doi:10.1371/journal.pone.0029923.t001
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treated with 5-Aza-29-Deoxicitidine as a control for calculating
relative expression. No significant changes in Mycn expression were
registered for either cell line. Statistically significant results based
on Student’s t-test (p value,0.05) were only obtained for Erbb2
expression in HH-16.cl.4. Erbb2 expression decreased after
treatment with 5-Aza-29-Deoxicitidine at a concentration of
3 mM in HH-16.cl.4 cells (Figure 9). This expression decrease,
although significant (p,0.05), was not high when compared with
the untreated cells. Moreover, Erbb2 expression continued to
decrease, even after the removal of the drug. These results show
that global genomic demethylation only affects the expression of
the Erbb2 gene in the HH-16.cl.4 cell line, whereas it appears to
have no effect on Mycn expression in either cell line.
Discussion
A major opportunity to increase our knowledge regarding the
biology of breast cancer is associated with the availability of
experimental model systems that recapitulate the many forms of
this disease. Recent studies have described the genetic character-
ization of breast cancer cell lines, showing their value in the
investigation of the role of genomic alterations in cancer
progression and as a resource for the discovery of new breast
cancer genes [25,26]. Rat cancer models, such as DMBA-induced
rat tumors, have been found to be useful models for studying
hormone-dependent breast cancer [1].
Here we present, for the first time, the genetic/cytogenetic
characterization of two DMBA-induced rat mammary tumor cell
Figure 5. Chromosome reconstruction of the clonal evolution in HH-16 cl.2/1 tumor cell line. Diagram showing the hypothetic clonal
evolution of HH-16 cl.2/1 chromosomes. In the diagram are shown numerical and structural clonal rearrangements. Ideograms represent all structural
clonal rearrangements. Each rat chromosome is represented by a different color according to the legend. Subclones A–H are presently found in the
cell line (respective karyotype formulas are shown in Table 1).
doi:10.1371/journal.pone.0029923.g005
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origin. These cell lines exhibit very distinct cytogenetic character-
istics, beginning with different levels of ploidy. While HH-16.cl.4
cell line presents a nearly tetraploid karyotype, showing a wide
range of cells with different chromosome numbers and levels of
ploidy (Figure 1D), a nearly diploid karyotype with low levels of
polyploidy can be found in HH-16 cl.2/1 (Figure 1C). This finding
might be indicative of a higher order of complexity and
chromosomal instability (CIN) of HH-16.cl.4, which is described
as the presence of ploidy changes as well as high levels of
aneuploidy [27]; these phenomena have been shown to have a
direct causal role in tumorigenesis [28]. Additionally, heterogene-
Table 2. Mycn and Erbb2 amplification and expression results for HH-16 cl.2/1 and HH-16.cl.4.
Mycn Erbb2
Cell line Mycn/RNO6
Expression Fold Change
(±SD) Erbb2/RNO10
Expression Fold
Change (±SD)
RNA in situ signal Mean
(±SD)
HH-16 cl.2/1 1.5 (84.6%) 21.4 (60.06) 1 (100%) +2.6 (60,1) 3.3 (60.9)
1.0 (15.4%)
HH-16.cl.4 1.0 (100%) +1.6 (60.2) 1.7 (88.6%) +10.7(61,2) 15.2 (63.6)
1.5 (5.6%)
1.3 (2.9%)
1.0 (2.9%)
Mycn and Erbb2 amplification results were calculated as the Mycn/RNO6 and Erbb2/RNO 10 ratios, respectively (values between brackets represent the percentage of
analyzed cells showing that result). Expression levels were accessed by RT-qPCR and RNA FISH (values between brackets represent the standard deviation).
doi:10.1371/journal.pone.0029923.t002
Figure 6. FISH results for Mycn and Erbb2 amplification analysis in HH-16 cl.2/1 and HH-16.cl.4cell lines. Images show Mycn hybridizes in
three chromosomes (A) two RNO6 and a derivative chromosome, der(19)t(6;19)(q14;q12) (B). Two Erbb2 signals are present in chromosome 10 (C)
identified with RNO10 paint probe hybridization (D).
doi:10.1371/journal.pone.0029923.g006
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number of apparently random chromosome changes, or so-called
‘‘cytogenetic noise’’. For this reason, performing genome-wide
cytogenetic characterization did not appear to be promising, and
cytogenetic analysis was limited to the identification of relevant
chromosome rearrangements associated with specific gene expres-
sion changes.
For the cytogenetic characterization of the HH-16 cl.2/1 cell
line a multi approach was used which included G-banding,
chromosome painting using rat and mouse probes and BAC/PAC
clones hybridization. Clonal chromosome rearrangements were
characterized (Figure 2) and specific breakpoint regions were
identified (Figure 3 and 4). Few studies on the cytogenetic
characterization of rat cell lines have been performed, particularly
using rat or mouse paint probes. However, there have been some
reports addressing rat tumor cell lines indicating RNO1 [3,29,30],
RNO3 [29], RNO6 [31] and RNO15 [32,33] as recurrent and/or
relevant chromosomes related to the tumorigenesis/tumor pro-
gression in mammary fibrosarcomas, endometrial adenocarcino-
mas and lung cancer. Also in our study rearrangements in those
chromosomes have been identified, as it is the case of the complex
rearrangement involving RNO15 (Figure 4), only detected using
the combination of varied cytogenetic tools. For this derivative
chromosome we propose the occurrence of a double inversion as
previously found in Acute Myeloid Leukemia karyotypes (e.g.,
[34,35,36]), and its presence in both RNO15 homologues can be
explained by the loss of the normal chromosome, followed by the
duplication of the abnormal homolog [37,38,39]. An interesting
finding was the loss of an entire X chromosome which was present
in all subclones identified. X chromosome loss has been described
in numerous human cancer cases corresponding to the inactive X
copy (e.g., [40,41]) identified by a detectable Barr body (classic
characteristic of X chromosome inactivation) [42,43]. During our
analysis of HH-16 cl.2/1 cells interphase nuclei, no Barr bodies
were found in the X chromosome territory identified with the rat
X paint probe (data not shown). This finding provides evidence
that the X chromosome present in this cell line is the active X
chromosome.
Assembly of the obtained data allowed us to deduce the clonal
evolution of this tumor, which is illustrated in Figure 5. This
diagram allows easy visualization of the ancestral and recent
rearrangements, as well as providing an overview of the
microevolutionary processes that have occurred in the progression
of this tumor cell line. Analyses of karyotype clonal evolution have
been performed previously in rats [32,44], showing its relevance in
the investigation of tumor progression. Moreover, the existence of
ancestral structural chromosome abnormalities suggests a relevant
role for these rearrangements in providing a selective advantage to
this tumor cell line. An in silico analysis was performed focused on
the breakpoint regions of the ancestral structural chromosome
rearrangements and demonstrated that almost all of the break-
point regions contain genes in the rat genome for which the
human homolog has been associated with breast cancer (Table
S1). This finding is relevant once translocations can lead to altered
gene activity either through the formation of a chimeric gene
product with cell transforming properties, or by juxtaposition of an
oncogene with a foreign activator element [45].
In the cytogenetic characterization of HH-16 cl.2/1, the Mycn
extra copy number was of particular note, especially because this
characteristic was present in all of the cells analyzed and was
considered to represent an ancestral condition. This observation
raised the possibility of relevance of the Mycn gene in mammary
tumor initiation and progression for both cell lines (once they are
related). MYCN is part of a large family of oncogenes found to be
amplified in human neuroblastomas and is correlated with
aggressiveness and a negative prognosis in this type of pediatric
cancer (reviewed by [46]). Mycn amplification has also been
observed in rat tumors, specifically in uterine endometrial
carcinomas [31,47], however, the available literature does not
include any investigation of MYCN amplification status in breast
cancer. Overall, Mycn amplification was not detected in the HH-
16 cl.2/1 or in HH-16.cl.4 cell lines, but an Mycn gain was found
in HH-16 cl.2/1 (Figure 6 and Table 2). Additional copies of
MYCN equal or less than 4-fold detected by FISH were considered
as an MYCN gain, following a study on neuroblastoma [48].
The other gene analyzed in the present study was Erbb2.I n
humans, ERBB2 gene amplification constitutes one of the most
important genetic alterations associated with human breast cancer
and was first correlated with poor patient prognosis by Slamon
and colleagues [9]. Hence, no Erbb2 amplification was found in the
HH-16 cl.2/1 cell line, while for HH-16.cl.4 a low level of
amplification was detected (Table 2). Chromosome painting data
showed that Erbb2 gain resulted from a chromosome alteration
involving Erbb2 gene locus resulting in its duplication (Figure 6C).
Amplified DNA can be observed in various forms, including
double minutes or amplified regions on a chromosome or
distributed across the genome [49]. This gene gain may act as a
precursor to further Erbb2 amplification, or it may represent an
alternative pathway for activating the oncogenic potential of this
gene.
Generally, gene amplification has been associated with
overexpression of the amplified gene(s) [49], although this
correlation is not absolute. Both genes expression (Mycn and
Erbb2) was accessed by RT-qPCR in the present work. Mycn RNA
Figure 7. Relative expression of Erbb2 and Mycn in the HH-16
cl.2/1 and HH-16.cl.4 cell lines. Expression results were obtained by
reverse transcription quantitative real time PCR, normalized with the
reference genes beta-actin and GAPDH and compared with a control
sample. Data is presented as mean corresponding to fold change
relative to the control sample (p,0.05). Error bars represent 6SD.
doi:10.1371/journal.pone.0029923.g007
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changes which is in accord with the absence of gene amplification
detected (Figure 7 and Table 2). These results also show that the
Mycn gain corresponding to the three loci presented in the HH-16
cl.2/1 cell line was not reflected in an RNA expression change.
With respect to ERBB2, the most frequently used method to
determine its expression in breast cancer is immunohistochemistry
(protein quantification) [50]. In human invasive duct carcinomas
of the breast, erbB-2 protein overexpression is particularly
frequent, and in most cases, this overexpression is caused by
ERBB2 gene amplification and associated with an unfavorable
prognosis [9,51]. Trastuzumab (Herceptin) is a humanized
monoclonal antibody directed against the extracellular domain
of the erbB-2 protein [52] that have been found to be effective
when in presence of high levels of this protein [53,54]. The ERBB2
gene and erbB-2 protein status (gene amplification/protein
overexpression) are considered useful markers for predicting the
response to a specific cancer therapy, and analysis of these markers
is mandatory for the identification of breast cancer patients that
are amenable to trastuzumab treatment. In addition to immuno-
histochemistry, other methods have proven reliable in determining
ERBB2 expression status, such as real-time reverse transcription
quantitative PCR [55,56]. In the present study, a 3-fold increase in
expression was considered to represent a significant expression
change [57]. Relevant RNA expression changes for Erbb2 were
detected only for HH-16.cl.4 (10.7-fold increase) (Figure 7 and
Table 2). This result correlates with the Erbb2 gene gain,
suggesting that the amplification, while low, may have played a
role in the overexpression of Erbb2 RNA in this cell line, although
it may not be the only mechanism involved. The involvement of
human chromosome 17 (harbors ERBB2) polysomy in erbB-2
protein expression has been discussed with some controversy [58];
however, some authors point to it as the cause of ERBB2
overexpression [59,60]. This cell line presents different levels of
ploidy, and most of the cells analyzed present three copies of
RNO10 (Figure 6D), suggesting the possible correlation of this
chromosome copy number with the observed Erbb2 expression
levels. Another possible explanation is transcriptional regulation,
which could have promoted the accumulation of Erbb2 mRNA in
the absence of high levels of amplification. Moreover, both older
and more recent studies show that ERBB2 RNA overexpression
does not always correspond to erbB-2 protein overexpression,
suggesting the existence of post-transcriptional regulation of
ERBB2 [61,62], which shows the relevance of using RT-qPCR
in routine assessment of ERBB2 overexpression in human breast
cancer in the clinical laboratory setting.
RNA FISH was used to measure Erbb2 expression, comple-
menting and validating the results of the RT-qPCR analysis. RNA
Figure 8. Expression analysis of Erbb2 by RNA fluorescent in situ hybridization. RNA fluorescent in situ hybridization of Erbb2 mRNA (green)
and ribosomal 18S (red) used as reference, in HH-16 cl.2/1 (A) and HH-16.cl.4 (B) cell lines. The number of signals distributed by 4 intervals (C) and the
mean number of signals for each cell line (error bars represents 6SD) (D) clearly showed differences in Erbb2 expression between the two cell lines,
being considerably higher in the HH-16.cl.4 cell line.
doi:10.1371/journal.pone.0029923.g008
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analysis of spatial gene expression patterns at a single-cell
resolution [63,64,65]. This approach allowed clear visualization
and semi-quantification of mRNA molecules in the cytoplasm,
allowing quantification of the expression of Erbb2 in both cell lines.
The RNA FISH data strongly supported the RT-qPCR expression
results, showing higher expression of Erbb2 in HH-16.cl.4 (4.6
times greater) compared with the sister cell line HH-16 cl.2/1
(Figure 8 and Table 2), demonstrating to be an excellent
technology when applied either alone or together with other
technique.
Interestingly, the expression of Erbb2 in the HH-16.cl.4 rat cell
line appears to be affected by global genome demethylation. In the
present study, HH-16 cl.2/1 and HH-16.cl.4 cells were treated
with 5-Aza-29-Deoxicitidine, promoting global genome demethyl-
ation. Statistically significant results were obtained for the Erbb2
gene in the HH-16.cl.4 cell line, although the variation was not
especially large (Figure 9). It has been demonstrated that ERBB2
gene is overexpressed and unmethylated (in its promoter) in
tumors and tumor cell lines, such as ovarian tumoral tissues and
MCF-7 cell line [66,67]. A similar study to ours was performed in
a rat chondrosarcoma cell line, in which an increase in Erbb2
expression was found after global genome demethylation [68].
Intriguingly, our data shows a decrease in Erbb2 expression after 5-
Aza-29-Deoxicitidine treatment. While in the rat chondrosarcoma
cell line, Erbb2 promoter unmethylation seems to be the main
cause for Erbb2 overexpression, our data suggests a different
pivotal epigenetic mechanism underlying the expression of this
gene. Candidate negative regulators of Erbb2 might be non-coding
RNAs that for instance promote the degradation of transcripts
[69]; or even other less understood epigenetic mechanisms such as
splicing regulation [70] can explain our results. Our findings
emphasize that future studies are mandatory to reveal the exact
epigenetic events involved in the regulation of Erbb2 expression,
and that HH-16.cl.4cell line is an excellent tool to complete this
task.
The cell lines used in the present work were generated
simultaneously from the DMBA-induced rat mammary tumor
[5], but despite having the same initial genetic background,
fibroblastoid H-16 cl.2/1 cell line apparently reflect mesenchymal
cells of the stromal part of the tumor, while the epitheloid HH-
16.cl.4 cell line display epithelial origin. The cell lines different
lineage, associated with the higher chromosomal instability
revealed by HH-16.cl.4 (explaining the Erbb2 overexpression here
observed), suggests different mechanisms involved in tumor
progression of both cell lines. In fact, HH-16.cl.4 exhibits a
mainly tetraploid number of chromosomes. Tetraploidy can arise
through a number of mechanisms, including cell fusion, mitotic
slippage and cytokinesis failure [71]. In addition, tetraploid cells
typically contain twice the normal complement of centrosomes
that promote aberrant mitotic divisions and chromosome
missegregation at a high frequency. Moreover, tetraploidy has
been shown to initiate chromosomal instability and has been found
to precede the development of CIN and aneuploidy in several
cancers (e.g. [72,73]). On the other hand, in the fibroblastoid H-16
cl.2/1 cell line, chromosome structure instability (CSI) seems to be
the distinguishing feature, whose mechanisms are now starting to
be disclosed [74]. Nevertheless, it seems that CSI can be the result
of errors in the DNA damage checkpoints, DNA repair pathways,
and/or mitotic segregation errors. However, mutations in proteins
that permit cell cycle progression in the presence of double
stranded breaks (e.g. p53, BRCA1, BRCA2, ATM and ATR) may
also facilitate CSI [75].
In conclusion, molecular cytogenetics, gene expression profiling
and examination of the influence of global demethylation on gene
expression were used to characterize two rat mammary cell lines,
H-16 cl.2/1 and HH-16.cl.4. All the presented results provide a
platform for future studies on tumor progression and encourage
the use of these cell lines as a model. In particular this study
highlights H-16 cl.2/1 and HH-16.cl.4 potential as models for
studying Erbb2 associated mechanisms and as experimental tools to
assist in the generation of new biotherapies.
We believe that the development of capable in vitro models of
human breast cancer is of crucial importance in the study of
cancer and, consequently, in the development of new therapeutics.
We are confident that his work has contributed to the validation of
this cellular model and to its use in future studies.
Supporting Information
Figure S1 Representative images of the in situ hybrid-
ization of putative Erbb2 BAC clones onto RNO meta-
phases. Both CH230-276G18 (A) and CH230-305O21 (B)
hybridize in different locations than the Erbb2 position determined
by [24]. Only CH230-162I16 hybridizes at the cytogenetic
position of Erbb2 in Rattus norvegicus (10q32.1) (C). PCR
amplification of Erbb2 in the three clones (D). Only for CH230-
162I16 BAC clone the expected 350 bp band is observed.
(PDF)
Figure S2 Chromosomal location of the clonal rear-
rangements breakpoint regions in HH-16 cl.2/1 cell
line. Clonal rearrangements breakpoint regions in HH-16 cl.2/
1cell line are displayed in the rat ideogram [20]. Each type of
rearrangement originated by the breakpoints is identified by a
specific color.
(PDF)
Figure 9. Relative expression analysis of Erbb2 in HH-16.cl.4
cells after treatment with 5-Aza-2-Deoxicitidine. Relative expres-
sion analysis of Erbb2 in HH-16.cl.4 cells treated with 5-Aza-29-
Deoxicitidine (HH-16.cl.4 5-AZA) and in HH-16.cl.4 cells after stopping
the treatment with 5-Aza-2-Deoxicitidine (HH-16.cl.4 5-AZA-STOP). HH-
16.cl.4 cells that were not treated with 5-Aza-29-Deoxicitidine served as
control (HH-16.cl.4 control). Data is presented as mean corresponding
to fold change relative to control sample (p,0.05). Error bars represent
6SD.
doi:10.1371/journal.pone.0029923.g009
Erbb2 In Vitro Cell Model
PLoS ONE | www.plosone.org 13 January 2012 | Volume 7 | Issue 1 | e29923Table S1 In silico analysis of breast cancer related
genes present in the most representative rat breakpoint
regions, and its correspondent human homolog.
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